Optimal Once-Daily Busulfan Administration in Pediatric Patients: A Simulation-Based Investigation of Intravenous Infusion Times
DOI: https://doi.org/10.2147/dddt.s451970
IF: 4.3188
2024-03-20
Drug Design Development and Therapy
Abstract:Yun Kim, 1 Sungha Moon, 2 Su-Jin Rhee 2 1 College of Pharmacy, Daegu Catholic University, Gyeongsan, 38430, Republic of Korea; 2 College of Pharmacy, Wonkwang University, Iksan, 54538, Republic of Korea Correspondence: Su-Jin Rhee, College of Pharmacy, Wonkwang University, Iksan, 54538, Republic of Korea, Tel +82-63-850-6822, Email Purpose: Pediatric patients receiving hematopoietic stem cell transplantation undergo regular administration of intravenous busulfan as a conditioning regimen. Once-daily regimen of busulfan has been proposed as a more convenient alternative to the traditional regimen, but it may increase the risk of toxicity such as veno-occlusive disease (VOD). The study aims to evaluate the pharmacokinetics (PKs) of once-daily regimens and investigate appropriate intravenous infusion times to reduce the risk of toxicity. Patients and methods: Once-daily busulfan dosing regimens for pediatric patient were reviewed and selected including EMA- and FDA-based once-daily dosing regimens. We generated busulfan PK data of virtual pediatric patients using a previously developed population PK model. PK profiles and proportion of patients achieving the referenced maximum concentration (Cmax) and exposure to busulfan were used to evaluate the appropriateness of both infusion time and dosing regimens. Results: Predicted PK profiles and exposure of busulfan showed relatively similar distributions for all once-daily dosing regimens. Most patients exceeded the referenced Cmax possibly associated with a high risk of VOD with all once-daily regimens when applied with 3 hours of infusion. Conclusion: While intravenous infusion of once-daily busulfan is typically administered over 3 hours, our findings emphasize the necessity of considering sufficient infusion times to ensure safe drug utilization and prevent toxicity, which will aid in optimal busulfan use in pediatric oncology. Keywords: busulfan, pediatrics, population pharmacokinetics, once-daily dosing regimen, infusion times Pediatric patients receiving allogeneic hematopoietic stem cell transplants (HSCT) frequently receive intravenous busulfan as part of their myeloablative conditioning regimens. 1 The clinical use of busulfan can be challenging due to its narrow therapeutic index and significant inter- and intra-individual pharmacokinetic (PK) variability, especially in young patients. 2,3 For example, underexposure of busulfan is linked to graft failure and disease recurrence, and overexposure is linked to toxicity such as acute graft versus-host disease. Therefore, determining the ideal busulfan exposure remains a challenge. 4 On the other hand, busulfan exhibits highly variable PK profiles among patients, and it has been reported that busulfan clearance per day varies among busulfan dosing days even within the same patient. 5 These factors suggest that intravenous busulfan in combination with dose targeting based on therapeutic drug monitoring (TDM) may be preferable to dosing without dose targeting in patients. Traditionally, Busulfan has been given to pediatric patients either intravenously or orally four times per day for four consecutive days. The optimal dosing regimens for Busulfan have been recommended by the FDA and EMA. According to the FDA label, pediatric patients weighing ≤12 kg should receive a 2-hour infusion of 1.1 mg/kg, while those weighing >12 kg should receive 0.8 mg/kg. 6 In contrast, the EMA label recommends a 2-hour infusion of 1.0 mg/kg for patients weighing 34 kg. 7 However these dosing regimens require frequent preparations and an uncomfortable administration at night. 6 To address these limitations, studies have reported that both once-daily and four-times-daily regimens have similar PK and clinical outcomes in both adults and children. Once-daily regimen has been found to be more convenient and practical. 8–12 Several studies have been conducted to develop a once-daily regimen of busulfan suitable for pediatric patients, and several regimens have been proposed. 13–19 For those studies, in general, a 3-hour infusion was applied when busulfan was administered once a day, and the appropriateness of the regimen was evaluated based on daily area under the concentration time curve (AUC) or 4-day total AUC. However, the optimal once-daily busulfan regimen has not been determined and is still being investigated. One of the primary side effects of busulfan is veno-occlusive disease (VOD), commonly known as sinusoidal obstruction syndrome (SOS), which is a fatal vascular d -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal